Welcome to our dedicated page for Ascendis Pharma A/S SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ascendis Pharma A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ascendis Pharma A/S's regulatory disclosures and financial reporting.
Ascendis Pharma A/S reported that its board granted an aggregate of 32,310 warrants to certain employees under Appendix 1a to its Articles of Association. Each warrant gives the right to subscribe for one ordinary share at an exercise price of US $249.84 per share, matching the closing price of the company’s American Depositary Shares on the grant date.
Subject to earlier vesting upon certain exit events and continued service, 25% of the warrants will vest one year after the grant date, while the remaining 75% will vest in equal monthly installments over the following 36 months. After this grant, warrants to subscribe for an additional 1,611,843 shares remain available for future grants under the Articles of Association.
Ascendis Pharma A/S is transitioning from ADSs to a direct listing of its ordinary shares on Nasdaq. The company plans to list its ordinary shares on The Nasdaq Global Select Market, with trading expected to begin on April 20, 2026 under the existing ticker “ASND.”
All outstanding American Depositary Shares will be mandatorily exchanged for ordinary shares on a one-for-one basis. The last trading day for ADSs on Nasdaq is expected to be April 17, 2026, after which holders will automatically receive ordinary shares through their brokers’ DTC accounts.
Ascendis Pharma A/S reports new Week 52 data from its Phase 2 COACH Trial, studying combination therapy with once-weekly TransCon CNP and once-weekly TransCon hGH in children with achondroplasia. The company states that TransCon hGH accelerated TransCon CNP’s benefits beyond linear growth, with substantial improvements in arm span, spinal canal dimensions, and lower limb alignment.
Ascendis notes previously reported Week 52 results from the same trial showing mean annualized growth velocity above the 97th percentile of average-stature children, with maintained safety and tolerability and no acceleration of bone age. The report is incorporated by reference into existing Form S-8 and Form F-3 registration statements and includes extensive forward-looking statement language outlining clinical, regulatory, manufacturing, commercial, and financial risks referenced to Ascendis’ Form 20-F and future SEC reports.
Ascendis Pharma A/S reports that the U.S. FDA has granted orphan drug exclusivity to YUVIWEL (navepegritide; developed as TransCon® CNP), and that YUVIWEL is now commercially available in the United States. YUVIWEL is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia and open epiphyses, providing continuous systemic exposure to CNP over the weekly dosing interval. The orphan drug exclusivity for YUVIWEL runs through February 27, 2033.
Ascendis Pharma A/S director Jean Jacques Bienaimé filed an initial ownership report showing a warrant position rather than common shares. He directly holds warrants exercisable for 9,160 Ordinary Shares, with an exercise price of $172.35 per share and expiration on June 10, 2035. The warrants vest 25% on June 10, 2026 and then in 36 equal monthly installments. The filing also indicates he holds no Ordinary Shares directly as of the reporting date, and notes that the position includes American Depositary Shares, with each ADS representing one Ordinary Share.
Ascendis Pharma A/S reports the closing of an exercise window for its outstanding warrants linked to ordinary shares. During this period, warrant holders exercised rights resulting in registered share capital increases of nominal DKK 399,438, bringing total share capital to nominal DKK 62,376,846.
The company issued 399,438 new ordinary shares against average cash consideration of approximately USD $92.10 per share, based on the DKK-USD exchange rate on March 30, 2026. Ascendis amended its articles of association to reflect the higher share capital, and the updated articles are attached as an exhibit.
Ascendis Pharma A/S reported the results of its Annual General Meeting, where shareholders representing 56,234,042 ordinary shares, or 90.16% of shares outstanding, were present or represented. All agenda items were approved with strong support across the ballot.
Shareholders adopted the audited annual report for the year ended December 31, 2025 and discharged the Board of Directors and management from liability. They also approved carrying forward the consolidated loss of EUR 228 million for 2025 into 2026 via accumulated deficit.
All incumbent Board members were re-elected and Jean-Jacques Bienaimé joined as a new non-executive director, with terms running until the 2027 annual meeting. Shareholders also renewed authority allowing the Board, until March 22, 2031, to repurchase up to nominal DKK 1,000,000 of shares or equivalent American Depositary Shares as treasury shares.
Ascendis Pharma A/S director William Fairey has filed an initial ownership report outlining his equity position in the company. The filing shows direct ownership of 2,117 Ordinary Shares, as well as warrants over 9,160 Ordinary Shares with an exercise price of $102.7000 per share that expire on September 13, 2032.
He also holds several grants of Restricted Stock Units representing 1,374, 2,070 and 1,930 underlying Ordinary Shares. Each restricted stock unit represents a contingent right to receive one American Depositary Share, and each ADS represents one Ordinary Share. The footnotes state that these RSUs vest on or beginning on March 1, 2027 under different installment schedules.
Ascendis Pharma A/S director Imani Siham has filed an initial ownership report showing equity and equity-linked holdings in the company. The filing lists 2,317 Ordinary Shares held directly. It also shows warrants over 9,160 Ordinary Shares with an exercise price of $102.70 per share, expiring on September 13, 2032.
In addition, Siham holds several grants of restricted stock units, each representing a contingent right to receive one American Depositary Share, which in turn represents one Ordinary Share. According to the footnotes, these restricted stock units vest on March 1, 2027 or in two or three equal annual installments beginning on that date and have no expiration date.
Ascendis Pharma A/S executive vice president and chief financial officer Scott Thomas Smith filed an initial statement of ownership showing a mix of direct equity and derivative awards linked to the company’s ordinary shares and American Depositary Shares.
He holds warrants over 45,000 ordinary shares at an exercise price of $37.18 expiring on December 12, 2027, another 45,000 at $62.17 expiring on December 11, 2028, 27,000 at $108.00 expiring on December 10, 2029, 22,755 at $176.28 expiring on December 10, 2030, and 14,504 at $139.65 expiring on December 9, 2031. These warrants are fully vested and currently exercisable. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, which vest beginning on March 1, 2027, and 2,517 ordinary shares outright. Each ordinary share is represented by one ADS.